Dov Elefant
Directeur Financier/CFO chez FEMASYS INC.
Fortune : - $ au 30/04/2024
Profil
Dov S.
Elefant is currently the Chief Financial Officer at Femasys, Inc. He previously held positions as Director-Accounting & Finance at Tetragenex Pharmaceuticals, Assistant Controller at Synvista Therapeutics, Controller at Lev Pharmaceuticals, Controller, VP-Finance & Administration at EpiCept Corp., Chief Financial Officer at Althera Medical Ltd., Chief Financial Officer & Vice President at Cellectar Biosciences, and Chief Financial Officer at Akari Therapeutics Plc.
Elefant received an undergraduate degree from Yeshiva University.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
FEMASYS, INC.
-.--% | 01/02/2024 | 0 ( -.--% ) | - $ | 30/04/2024 |
Postes actifs de Dov Elefant
| Sociétés | Poste | Début |
|---|---|---|
| FEMASYS INC. | Directeur Financier/CFO | 28/02/2022 |
Anciens postes connus de Dov Elefant
| Sociétés | Poste | Fin |
|---|---|---|
| CELLECTAR BIOSCIENCES, INC. | Directeur Financier/CFO | 23/02/2022 |
| AKARI THERAPEUTICS, PLC | Directeur Financier/CFO | 15/09/2019 |
Althera Medical Ltd.
 Althera Medical Ltd. Medical SpecialtiesHealth Technology Althera Medical Ltd. develops therapeutic devices for the treatment of various cancers. The private company is based in Bnei Braq, Israel. | Directeur Financier/CFO | - |
Lev Pharmaceuticals, Inc.
 Lev Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Lev Pharmaceuticals, Inc. develops and commercializes therapeutic products for the treatment of inflammatory diseases. It researches a series of drugs to fight both edema and heart attacks. The company is located in New York. | Comptroller/Controller/Auditor | 01/02/2009 |
EpiCept Corp.
 EpiCept Corp. Pharmaceuticals: MajorHealth Technology EpiCept Corp. is a pharmaceutical company, which focuses on the clinical development and commercialization of pharmaceutical products for the treatment of cancer and pain. The company focuses on analgesics targeting peripheral nerve receptors and cancer therapies. Its lead product Ceplene, is used concomitantly with low-dose interleukin-2, is intended as remission maintenance therapy in the treatment of acute myeloid leukemia for adult patients. The company's other oncology compounds include AmiKet, a late-stage pain product candidate for the treatment of peripheral neuropathies, and two other oncology compounds in clinical development, that that were discovered using in-house technology and have been shown to act as vascular disruption agents in solid tumors. EpiCept was founded in March 1993 and is headquartered in Tarrytown, NY. | Directeur Financier/CFO | 01/03/2007 |
Formation de Dov Elefant
| Yeshiva University | Undergraduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 4 |
|---|---|
| SYNVISTA THERAPEUTICS, INC. | Health Technology |
| AKARI THERAPEUTICS, PLC | Health Technology |
| CELLECTAR BIOSCIENCES, INC. | Health Technology |
| FEMASYS INC. | Electronic Technology |
| Entreprise privées | 5 |
|---|---|
EpiCept Corp.
EpiCept Corp. Pharmaceuticals: MajorHealth Technology EpiCept Corp. is a pharmaceutical company, which focuses on the clinical development and commercialization of pharmaceutical products for the treatment of cancer and pain. The company focuses on analgesics targeting peripheral nerve receptors and cancer therapies. Its lead product Ceplene, is used concomitantly with low-dose interleukin-2, is intended as remission maintenance therapy in the treatment of acute myeloid leukemia for adult patients. The company's other oncology compounds include AmiKet, a late-stage pain product candidate for the treatment of peripheral neuropathies, and two other oncology compounds in clinical development, that that were discovered using in-house technology and have been shown to act as vascular disruption agents in solid tumors. EpiCept was founded in March 1993 and is headquartered in Tarrytown, NY. | Health Technology |
Lev Pharmaceuticals, Inc.
Lev Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Lev Pharmaceuticals, Inc. develops and commercializes therapeutic products for the treatment of inflammatory diseases. It researches a series of drugs to fight both edema and heart attacks. The company is located in New York. | Health Technology |
Tetragenex Pharmaceuticals, Inc.
 Tetragenex Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Tetragenex Pharmaceuticals, Inc. operates as a biotechnology company. It develops and commercializes proprietary pharmaceutical products for use in treatment resistant depression and other central nervous system diseases in the United States. The firm's principal product is Nemifitide, an antidepressant compound, which is in Phase II clinical trials for the treatment of depression, anxiety, and other central nervous system disorders. The company was founded in 1989 and is headquartered in Syosset, NY. | Health Technology |
Celsus Therapeutics Plc
 Celsus Therapeutics Plc Pharmaceuticals: MajorHealth Technology Celsus Therapeutics Plc is a drug development company, which focuses on developing novel, first-in-class, non-steroidal, synthetic anti-inflammatory drugs and multi-functional anti-inflammatory drugs. The company main clinical candidates are MRX-5, MRX-6, MRX-4, CFX-1 and OPX-1. Celsus Therapeutics was founded on October 7, 2004 and is headquartered in London, the United Kingdom. | Health Technology |
Althera Medical Ltd.
Althera Medical Ltd. Medical SpecialtiesHealth Technology Althera Medical Ltd. develops therapeutic devices for the treatment of various cancers. The private company is based in Bnei Braq, Israel. | Health Technology |
